<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04218084</url>
  </required_header>
  <id_info>
    <org_study_id>GBT440-032</org_study_id>
    <nct_id>NCT04218084</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease</brief_title>
  <acronym>HOPE Kids 2</acronym>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Blood Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Blood Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 3, randomized, double-blind, placebo-controlled study of voxelotor in
      pediatric participants, aged ≥ 2 to &lt; 15 years old, with Sickle Cell Disease. The primary
      objective is to evaluate the effect of voxelotor on the TCD (Transcranial Doppler Ultrasound)
      measurements in SCD participants in this age range.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase 3, randomized, double-blind, placebo-controlled study of voxelotor in
      pediatric participants, aged ≥ 2 to &lt; 15 years old, with Sickle Cell Disease. The study will
      be conducted at approximately 50 international clinical sites, and will enroll approximately
      224 participants. Participants will be randomized in a 1:1 ratio to receive voxelotor or
      placebo. All participants younger than 12 years of age and randomized to voxelotor will
      receive a dose based on their body weight, to provide exposure corresponding to the adult
      dose of 1500 mg/day.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-Blind, Placebo-Controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>TCD Measurement</measure>
    <time_frame>24 weeks</time_frame>
    <description>The change in time averaged maximum of the mean velocity (TAMMV) arterial cerebral blood flow, as measured by TCD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in TCD Flow Velocity</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion to Abnormal TCD Flow Velocity</measure>
    <time_frame>24, 48, and 96 weeks</time_frame>
    <description>Incidence of conversion to abnormal TCD flow velocity (≥ 200 cm/sec)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reversion to Normal TCD Flow Velocity</measure>
    <time_frame>24, 48, and 96 weeks</time_frame>
    <description>Incidence of reversion to normal TCD flow velocity (&lt;170 cm/sec)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TCD Flow Velocity Reduction</measure>
    <time_frame>24, 48, and 96 weeks</time_frame>
    <description>Proportion of participants with TCD flow velocity reduction ≥ 15 cm/sec</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Change in Hemoglobin (Hb)</measure>
    <time_frame>24, 48, and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Unconjugated Bilirubin</measure>
    <time_frame>24, 48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percent of Reticulocyte</measure>
    <time_frame>24, 48, and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Absolute Reticulocyte</measure>
    <time_frame>24, 48, and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lactate Dehydrogenase (LDH)</measure>
    <time_frame>24, 48, and 96 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">224</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Voxelotor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Voxelotor 1500mg or equivalent daily as a tablet or as powder for oral suspension.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voxelotor</intervention_name>
    <description>Participants are randomized 1:1 to receive voxelotor or placebo.</description>
    <arm_group_label>Voxelotor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Matching placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female participants with Sickle Cell Anemia (SCA)

          2. TCD time averaged maximum of the mean velocity (TAMMV) arterial cerebral blood flow ≥
             170 to &lt; 200cm/sec during the Screening Period

          3. Hb ≥ 5.5 and ≤ 10.5 g/dL during screening

          4. For participants taking HU, the dose of HU (mg/kg) must be stable for at least 90 days
             prior to signing the informed consent form (ICF) and/or assent form, and with no
             anticipated need for dose adjustments (other than weight based) or for initiation of
             HU for non-chronic use during the study, in the opinion of the Investigator

          5. Written informed parental/guardian consent and participant assent (where applicable)
             has been obtained per IRB/EC policy and requirements, consistent with ICH guidelines.

        Exclusion Criteria:

          1. Body weight &lt; 5kg at the screening visit

          2. Hospitalization for VOC or acute chest syndrome (ACS) within the 14 days prior to
             execution of informed consent/assent (see Section 7.2.5.1 for the definition of VOC).

          3. More than 10 VOCs within the past 12 months that required hospitalization, emergency
             room, or clinic visit

          4. Stroke resulting in focal neurological deficit; previous silent infarcts are
             permitted.

          5. Known history or findings, including screening magnetic resonance imaging
             (MRI)/magnetic imaging angiography (MRA) findings, suggestive of significant cerebral
             vasculopathy (eg, moyamoya or significant vasculopathy)

          6. History of seizure disorder (History of febrile seizures is permissible if there have
             been no seizures within the 12 months prior to randomization).

          7. Has been treated with erythropoietin or other hematopoietic growth factors within 28
             days of signing informed consent/assent or if, in the opinion of the Investigator,
             there is an anticipated need for such agents during the study

          8. RBC transfusion therapy (also termed chronic, prophylactic, or preventative
             transfusion) or has received an RBC transfusion or exchange transfusion for any reason
             within 90 days of signing the informed consent/assent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Margaret Tonda, PharmD</last_name>
    <phone>(650) 741-7761</phone>
    <email>mtonda@gbt.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jenni Herber</last_name>
    <phone>(650) 826-2422</phone>
    <email>jherber@gbt.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Howard, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Howard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Jesus Carhuas</last_name>
      <phone>202-476-3578</phone>
      <email>ccarhuas@childrensnational.org</email>
    </contact>
    <investigator>
      <last_name>Andrew Campbell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Medical Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah J Acado</last_name>
      <phone>305-243-2930</phone>
      <email>s.acado@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Ofelia Alvarez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta-Hughes Spalding</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Toi Dickson</last_name>
      <phone>404-843-4410</phone>
      <email>tdickson@mtvcr.com</email>
    </contact>
    <investigator>
      <last_name>Robert Brown, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta-Scottish Rite</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adelphos Azilah</last_name>
      <phone>408-785-2572</phone>
      <email>adelphos.azilah@choa.org</email>
    </contact>
    <investigator>
      <last_name>Robert Brown, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kellsey Smith</last_name>
      <phone>312-227-4824</phone>
      <email>kellsmith@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Robert Liem, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charmaine Williams-Farr</last_name>
      <phone>313-966-8393</phone>
      <email>cwilliam8@med.wayne.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Callaghan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospitals &amp; Clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ann Mehrhof</last_name>
      <phone>816-302-6808</phone>
      <email>amehrhof@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Gerald Woods, MD, FAAP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kusal Mihindukulasuriya</last_name>
      <phone>314-747-0795</phone>
      <email>klmihind@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Monica Hulbert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amy Hawkins</last_name>
      <phone>252-744-0514</phone>
      <email>hawkinsam19@ecu.edu</email>
    </contact>
    <investigator>
      <last_name>Beng Fuh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Courtney Babb</last_name>
      <phone>267-426-9338</phone>
      <email>babbc@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Kim Smith-Whitley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ram Kalpatthi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ram Kalpatthi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Alston</last_name>
      <phone>843-876-8652</phone>
      <email>alstonch@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Shayla Bergmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristen Ryan</last_name>
      <phone>901-595-5685</phone>
      <email>kristen.ryan@stjude.org</email>
    </contact>
    <investigator>
      <last_name>Jeremie Estepp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chukwuma Kalu</last_name>
      <phone>832-834-4659</phone>
      <email>cokalu@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Venee Tubman, MD, MSSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zagazig University Hospital</name>
      <address>
        <city>Zagazig</city>
        <state>Al Sharkeya</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mohamed Badr, MD, MBBCH</last_name>
    </contact>
    <investigator>
      <last_name>Mohamed Badr, MD, MBBCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alexandria University Hospital</name>
      <address>
        <city>Alexandria</city>
        <zip>21131</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hoda Hassab, MBCHB, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Hoda Hassab, MBCHB, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ain Shams University Hospital</name>
      <address>
        <city>Cairo</city>
        <zip>11566</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Azza Tantawy, MBBCH</last_name>
    </contact>
    <investigator>
      <last_name>Azza Tantawy, MBBCH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abu El Rich Hospital, Cairo University Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amal El-Beshlawy, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Amal El-Beshlawy, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korle-Bu Teaching Hospital Child Health</name>
      <address>
        <city>Accra</city>
        <country>Ghana</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine Segbefia</last_name>
    </contact>
    <investigator>
      <last_name>Catherine Segbefia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Komfo Anokye Teaching Hospital Research and Development Unit</name>
      <address>
        <city>Kumasi</city>
        <country>Ghana</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuel Asafo-Adjei</last_name>
    </contact>
    <investigator>
      <last_name>Emmanuel Asafo-Adjei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniela Cuzzubbo</last_name>
    </contact>
    <investigator>
      <last_name>Daniela Cuzzubbo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seconda Università degli Studi di Napoli</name>
      <address>
        <city>Napoli</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silverio Perrotta</last_name>
    </contact>
    <investigator>
      <last_name>Silverio Perrotta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raffaella Colombatti, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Raffaella Colombatti, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CREATES - Strathmore University Medical Centre</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernhards Ogutu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bernhards Ogutu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gertrude's Children's Hospital</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessie Githanga, MBChB, MMed</last_name>
    </contact>
    <investigator>
      <last_name>Jessie Githanga, MBChB, MMed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KEMRI - Centre for Respiratory Disease Research (CRDR)</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Videlis Nduba, MD</last_name>
    </contact>
    <investigator>
      <last_name>Videlis Nduba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sultan َQaboos University Hospital - Adults/Adolescents</name>
      <address>
        <city>Muscat</city>
        <country>Oman</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Salam Al Kindi, FRCP</last_name>
    </contact>
    <investigator>
      <last_name>Salam Al Kindi, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sultan َQaboos University Hospital - Pediatrics</name>
      <address>
        <city>Muscat</city>
        <country>Oman</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yasser Wali</last_name>
    </contact>
    <investigator>
      <last_name>Yasser Wali</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King Abdullah Children's Specialist Hospital</name>
      <address>
        <city>Riyadh</city>
        <zip>14611</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mohamed Essa</last_name>
    </contact>
    <investigator>
      <last_name>Mohamed Essa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King Fahd Medical City</name>
      <address>
        <city>Riyadh</city>
        <zip>14611</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alaa Mursi</last_name>
    </contact>
    <investigator>
      <last_name>Alaa Mursi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King Saud University</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ali Al Shehri</last_name>
    </contact>
    <investigator>
      <last_name>Ali Al Shehri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Telfer, DM</last_name>
    </contact>
    <investigator>
      <last_name>Paul Telfer, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evelina Childrens Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Baba Inusa, MBBS</last_name>
    </contact>
    <investigator>
      <last_name>Baba Inusa, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SE5 9NU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Subarna Chakravorty</last_name>
    </contact>
    <investigator>
      <last_name>Subarna Chakravorty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
    <country>Ghana</country>
    <country>Italy</country>
    <country>Kenya</country>
    <country>Oman</country>
    <country>Saudi Arabia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 20, 2019</study_first_submitted>
  <study_first_submitted_qc>January 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2020</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Transcranial Doppler Ultrasound (TCD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

